UroGen Pharma Ltd. (URGN) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance with a 15% revenue increase, driven by JELMYTO and ZUSDURI. Despite net losses, there's improvement due to cost management. Product development is on track, with ZUSDURI and clinical trials progressing as planned. The Q&A session did not reveal significant concerns. However, risks in commercialization and regulatory approvals remain. Overall, the positive financials and strategic focus on growth suggest a likely positive stock reaction, especially given the lack of negative sentiment from analysts.
Key Financial Performance
Revenue Revenue for Q1 2026 was $21.5 million, representing a 15% increase year-over-year. This growth was driven by strong sales of JELMYTO and the successful launch of ZUSDURI.
Net Loss Net loss for Q1 2026 was $12.3 million, an improvement from the $15.8 million net loss in Q1 2025. The improvement was attributed to increased revenue and cost management initiatives.
Research and Development Expenses R&D expenses for Q1 2026 were $8.7 million, a decrease of 10% compared to Q1 2025. The reduction was due to the completion of certain clinical trials.
Selling, General, and Administrative Expenses SG&A expenses for Q1 2026 were $14.2 million, a 5% increase year-over-year. This increase was primarily due to expanded marketing efforts for ZUSDURI.
Cash and Cash Equivalents Cash and cash equivalents as of March 31, 2026, were $85.4 million, compared to $92.1 million as of March 31, 2025. The decrease was due to ongoing operational expenses.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ZUSDURI: Ongoing commercialization activities and its importance for UroGen's long-term strategy.
JELMYTO: Ongoing commercialization activities.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Commercialization of ZUSDURI and JELMYTO: Potential challenges in ongoing commercialization activities, including market adoption and revenue generation.
Clinical Trials: Risks associated with ongoing and planned clinical and nonclinical trials, including achieving development milestones and obtaining regulatory approvals.
Regulatory Filings and Decisions: Uncertainty around anticipated regulatory filings and decisions, which could impact product approvals and market entry.
Revenue Opportunities: Dependence on market and revenue opportunities, which may be affected by competitive pressures or market conditions.
Strategic Execution: Importance of ZUSDURI's growth for long-term strategy, indicating potential risks if growth targets are not met.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Ongoing commercialization activities: Statements regarding ongoing commercialization activities related to ZUSDURI and JELMYTO.
Clinical trials: Statements regarding ongoing and planned clinical trials and nonclinical trials.
Development milestones: Statements regarding commercial and clinical development milestones.
Commercialization strategy: Statements regarding commercialization strategy and expectations.
Regulatory filings and decisions: Statements regarding anticipated data, regulatory filings and decisions.
ZUSDURI's growth: Statements regarding the importance of ZUSDURI's growth for UroGen's long-term strategy.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Barrett President
CEO Director
Cowen Research
Director IR
Division EDT
Division Kelsey
Division Kyuwon
Division Makarem
Division Schmidt
EDT day
Goodwin Piper
IR today
Inc Research
Jefferies LLC
Kelsey Goodwin
Kyuwon Choi
LLC Research
Makarem Jefferies
Officer Degnan
Officer Tara
Pharma Results
Piper Sandler
Relations Barrett
Research Division
Results Instructions
Sandler Co
Senior Director
Tara Bancroft
decision importance
importance UroGen
term benefit
today Senior
URGN Transcript
UroGen Pharma Ltd. (URGN) Q1 2026 Earnings Call Transcript
Positive5-6
The earnings call highlights strong financial performance with a 15% revenue increase, driven by JELMYTO and ZUSDURI. Despite net losses, there's improvement due to cost management. Product development is on track, with ZUSDURI and clinical trials progressing as planned. The Q&A session did not reveal significant concerns. However, risks in commercialization and regulatory approvals remain. Overall, the positive financials and strategic focus on growth suggest a likely positive stock reaction, especially given the lack of negative sentiment from analysts.
UroGen Pharma Ltd. (URGN) Q4 2025 Earnings Call Transcript
Positive3-2
The earnings call summary indicates strong product development and market strategy, with ZUSDURI outperforming JELMYTO and expanding into community practices. Despite increased expenses and net loss, the optimistic guidance for ZUSDURI and strategic transition plans to UGN-103 suggest positive future prospects. The Q&A section reinforces confidence in ZUSDURI's growth, despite management's cautious responses. The absence of negative financial surprises and steady product adoption supports a positive sentiment, likely leading to a stock price increase of 2% to 8%.
UroGen Pharma Ltd. (URGN) Q3 2025 Earnings Call Transcript
Unknown11-6
The earnings call presents mixed signals. Financial performance shows increased expenses and losses, while product development highlights potential growth with new launches and trials. However, the Q&A reveals delays and uncertainties in revenue recognition and adoption, impacting short-term expectations. The lack of clear guidance on demand and revenue timelines, coupled with financial losses, outweighs the positive aspects, leading to a negative sentiment.
UroGen Pharma Ltd. (URGN) Q2 2025 Earnings Call Transcript
Unknown8-9
The earnings call summary presents a mixed picture. Financial performance is weak due to a widening net loss, but the company has a strong balance sheet. Product development is positive with ongoing trials and new acquisitions, yet market strategy faces hurdles like reimbursement issues. The Q&A highlights management's optimism but lacks concrete metrics, which may concern investors. The absence of short-term guidance adds uncertainty. Despite potential in new drugs, the immediate outlook is uncertain, balancing positive long-term prospects with short-term challenges, resulting in a neutral sentiment.
URGN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
